GlassScriptPhysician profile
Diane Knapp
NPI 1912090499
$9,566.56
in general payments reported to CMS, 2019-2025
42 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,022 · 2022: $2,132 · 2023: $1,970 · 2024: $1,882 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,388 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,388.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,223.21 | 2021-2025 | Unithroid |
| Abbvie INC. | $961.61 | 2021-2025 | |
| Lilly USA, LLC | $729.49 | 2021-2025 | Jardiance, Mounjaro, Humulin |
| Astrazeneca Pharmaceuticals LP | $712.58 | 2021-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $530.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $392.67 | 2021-2025 | Repatha, Tepezza, Repatha |
| Medtronic, INC. | $359.50 | 2021-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $345.11 | 2021-2023 | Verquvo |
| Glaxosmithkline, LLC. | $294.45 | 2022-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $290.88 | 2022-2024 | |
| Corcept Therapeutics | $271.51 | 2022-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $258.17 | 2021-2023 | Xarelto |
| Amarin Pharma, INC. | $243.70 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $240.65 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Currax Pharmaceuticals LLC | $235.24 | 2021-2023 | Nexletol, Onzetra Xsail, Contrave |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $214.51 | 2021-2025 | |
| Astellas Pharma US INC | $177.04 | 2022-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $175.61 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $168.45 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $164.62 | 2021-2025 | |
| Madrigal Pharmaceuticals | $160.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $145.43 | 2021-2025 | Nexletol |
| Evoke Pharma, INC. | $139.70 | 2022-2025 | Gimoti |
| Vivus LLC | $139.55 | 2021-2024 | Qsymia |
| Amphastar Pharmaceuticals, INC. | $114.19 | 2025 | |
| Sanofi-Aventis U.S. LLC | $111.66 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $102.62 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $74.31 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $66.70 | 2021-2025 | Isturisa |
| Avanir Pharmaceuticals, INC. | $65.20 | 2021 | |
| Insulet Corporation | $59.65 | 2021-2025 | Omnipod |
| Averitas Pharma INC. | $57.33 | 2025 | Qutenza |
| Ultragenyx Pharmaceutical INC. | $57.14 | 2021-2023 | Crysvita |
| Alexion Pharmaceuticals, INC. | $54.30 | 2024-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.67 | 2023-2024 | Jardiance, Tradjenta |
| Nevro Corp. | $37.68 | 2021 | |
| Horizon Therapeutics Plc | $33.86 | 2023 | Tepezza |
| Sequel Med Tech, LLC | $29.16 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $26.04 | 2025 | Yorvipath |
| Exact Sciences Corporation | $24.91 | 2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $21.69 | 2023 | |
| Alfasigma USA, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.